Heliogen (NYSE:HLGN) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.06) by 83.33 percent.
Reported Late Thursday March 30, INVO Provides Preliminary Update On FY2022 Financial Results; Sees Q4 Revenue $270K-$280K Vs $235.321K QoQ
INVO Bioscience, Inc. (NASDAQ:INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device